Patent classifications
C12Q1/533
METHODS AND REAGENTS FOR ANALYZING PROTEIN-PROTEIN INTERFACES
The present disclosure provides methods and reagents useful for analyzing protein-protein interfaces such as interfaces between a presenter protein (e.g., a member of the FKBP family, a member of the cyclophilin family, or PIN1) and a target protein. In some embodiments, the target and/or presenter proteins are intracellular proteins. In some embodiments, the target and/or presenter proteins are mammalian proteins.
METHODS AND REAGENTS FOR ANALYZING PROTEIN-PROTEIN INTERFACES
The present disclosure provides methods and reagents useful for analyzing protein-protein interfaces such as interfaces between a presenter protein (e.g., a member of the FKBP family, a member of the cyclophilin family, or PIN1) and a target protein. In some embodiments, the target and/or presenter proteins are intracellular proteins. In some embodiments, the target and/or presenter proteins are mammalian proteins.
METHODS AND COMPOSITION FOR MODIFYING ENZYMES
Aspects of the disclosure relate to compositions of enzyme-binding polypeptides (EBPs) that modify the substrate specificity of an enzyme and a method for identifying an EBP that modifies substrate specificity of an enzyme binding at least one substrate, the method comprising: contacting the enzyme with a polypeptide library comprising a plurality of EBPs that bind different epitopes of the enzyme; identifying EBPs that bind to the enzyme to form an EBP-enzyme complex; assaying for the activity level and substrate specificity of the EBP-enzyme complex; and identifying EBPs that modify the substrate specificity of the enzyme by identifying EBPs that, when in an EBP-enzyme complex, have a different substrate specificity than un-complexed EBP; wherein the catalytic rate constant of the EBP-enzyme complex is 50% of the un-complexed enzyme for at least one substrate and/or wherein the EBP-enzyme complex retains binding to a substrate.
RUBBER-LIKE MATERIAL FOR THE IMMOBILIZATION OF PROTEINS AND ITS USE IN LIGHTING, DIAGNOSIS AND BIOCATALYSIS
The present invention relates to a process of preparing a rubber-like material containing a protein immobilized therein, as well as a corresponding rubber-like material, the process comprising the steps of (a) mixing a protein, a branched polymer such as trimethylolpropane ethoxylate and a linear polymer such as poly(ethylene oxide) in an aqueous solution to form a gel, and (b) drying the gel to obtain a rubber-like material containing the protein immobilized therein, wherein the branched polymer comprises at least three polymeric branches bound to a central branching unit. The rubber-like material allows the immobilization and stabilization of a wide range of different proteins, including luminescent proteins as well as enzymes, and can particularly advantageously be used as down-converting material for light-emitting diodes (LEDs), for diagnostic applications, and in bioreactors.
RUBBER-LIKE MATERIAL FOR THE IMMOBILIZATION OF PROTEINS AND ITS USE IN LIGHTING, DIAGNOSIS AND BIOCATALYSIS
The present invention relates to a process of preparing a rubber-like material containing a protein immobilized therein, as well as a corresponding rubber-like material, the process comprising the steps of (a) mixing a protein, a branched polymer such as trimethylolpropane ethoxylate and a linear polymer such as poly(ethylene oxide) in an aqueous solution to form a gel, and (b) drying the gel to obtain a rubber-like material containing the protein immobilized therein, wherein the branched polymer comprises at least three polymeric branches bound to a central branching unit. The rubber-like material allows the immobilization and stabilization of a wide range of different proteins, including luminescent proteins as well as enzymes, and can particularly advantageously be used as down-converting material for light-emitting diodes (LEDs), for diagnostic applications, and in bioreactors.
Materials and methods for identifying gyrase inhibitors
The disclosure describes the effects of transcription mediated from a promoter on the transcription mediated by divergently coupled supercoiling-sensitive promoter. Transcription initiated from a promoter inhibits transcription mediated by a specific supercoiling-sensitive promoter that is divergently coupled to the promoter. A gyrase inhibitor relieves this inhibition and substantially increases the transcription mediated by the specific supercoiling-sensitive promoter that is divergently coupled to another promoter. Accordingly, the invention pertains to a method for identifying a compound as a gyrase inhibitor or not a gyrase inhibitor based on differential expression of genes under the control of divergently coupled promoters in the presence of the compound. Another embodiment of the invention provides an assay for identifying one or more compounds from a library of compounds as a gyrase inhibitor. Polynucleotides and cells containing such polynucleotides that are suitable for carrying out the methods described herein are also provided.
PROSTATE CANCER-ASSOCIATED SECRETED PROTEINS
Methods are provided for treating a subject with prostate cancer and/or diagnosing a subject at risk for prostate cancer, which can include measuring increased expression of at least two prostate cancer-related molecules in a sample obtained from a subject, including the prostate cancer-related molecules AGR2, AGR3, CRISP3, CCL3, CEACAM5, CEACAM6, IL24, MMP9, CXCL14, CD90, POSTN, and SFRP4. The methods can include administering at therapy to a subject with prostate cancer. Methods are provided for treating a subject with intermediate- or high-risk prostate cancer, which can include measuring increased expression of MMP9 in a sample obtained from a subject compared to a control representing expression of MMP9 expected in a sample from a subject who has low-risk prostate cancer.
PROSTATE CANCER-ASSOCIATED SECRETED PROTEINS
Methods are provided for treating a subject with prostate cancer and/or diagnosing a subject at risk for prostate cancer, which can include measuring increased expression of at least two prostate cancer-related molecules in a sample obtained from a subject, including the prostate cancer-related molecules AGR2, AGR3, CRISP3, CCL3, CEACAM5, CEACAM6, IL24, MMP9, CXCL14, CD90, POSTN, and SFRP4. The methods can include administering at therapy to a subject with prostate cancer. Methods are provided for treating a subject with intermediate- or high-risk prostate cancer, which can include measuring increased expression of MMP9 in a sample obtained from a subject compared to a control representing expression of MMP9 expected in a sample from a subject who has low-risk prostate cancer.
Methods and reagents for analyzing protein-protein interfaces
The present disclosure provides methods and reagents useful for analyzing protein-protein interfaces such as interfaces between a presenter protein (e.g., a member of the FKBP family, a member of the cyclophilin family, or PIN1) and a target protein. In some embodiments, the target and/or presenter proteins are intracellular proteins. In some embodiments, the target and/or presenter proteins are mammalian proteins.
Methods and reagents for analyzing protein-protein interfaces
The present disclosure provides methods and reagents useful for analyzing protein-protein interfaces such as interfaces between a presenter protein (e.g., a member of the FKBP family, a member of the cyclophilin family, or PIN1) and a target protein. In some embodiments, the target and/or presenter proteins are intracellular proteins. In some embodiments, the target and/or presenter proteins are mammalian proteins.